Ancora Pharmaceuticals Receives Federal Grant for Malaria and Staphylococcal Vaccine Development

MEDFORD, Mass.--(BUSINESS WIRE)--Ancora Pharmaceuticals announced today that it received two federal grants under the Qualifying Therapeutic Discovery Program to continue funding its groundbreaking research and development of vaccine candidates to prevent malaria and infection by staphylococcus aureus.
MORE ON THIS TOPIC